← Back to all trials
Active Not Recruiting
NCT05527418
Safety, Tolerance and Antiretroviral Activity of Dasatinib: a Pilot Clinical Trial in Patients With Recent HIV-1 Infection
Conditions: Recent HIV-1 Infection
Sex: All
Ages: 18 Years – 65 Years
Healthy volunteers: No
Phase: PHASE2
Enrollment: 24
Sponsor: Eva Bonfill
Location: Eva Bonfill Barcelona
Summary
Study to evaluate the safety, tolerability and antiretroviral activity of a new therapeutic strategy, based on the administration of dasatinib, an ITK, in patients with recent (3-12 months) asymptomatic HIV-1 infection.
Eligibility Criteria
Inclusion Criteria:
* 18 to 65 years.
* Documented asymptomatic HIV-1 infection of more than 3 months' duration (all patients must have a positive Western blot, including the p31 band whose appearance indicates infection of more than 90 days duration).
* Not having received ART
* CD4 T-lymphocyte count\> 350 / μl
* Patient giving written informed consent
Exclusion Criteria:
* Active HBV (HBsAg+ or DNA+) and/or HCV (RNA+) infection in screening.
* ALT\> 2 UNL, glomerular filtration rate \
Source: ClinicalTrials.gov (NCT05527418). StuddyBuddy aggregates publicly available trial information.
